A new study has found that polymorphisms in the host gene kif1C, which encodes a kinesin-like motor protein, determine whether mouse macrophages are resistant or sensitive to anthrax lethal toxin. These findings may lead the way to discovering how both germ and host factors might contribute to a lethal infection.
These host differences, some of them quite subtle, fall between species, groups and even individuals, and can clearly govern whether one exposed person may become mildly ill, another gravely ill and a third not ill at all. Deconvoluting the innumerable complexities of both the microbe and the host, and all the potential vying interactions between their molecules, currently confounds even our most advanced models. More data are ever required! Still, with the advent of modern methods for genomic, proteomic and global genetic analysis, delineation of all molecular interactions occurring between host and pathogen is perhaps approachable. But distilling out of the immense profusion of old and new information the key molecules and interactions that might aid in countering the infection remains a cardinal challenge.
Bill Dietrich and colleagues at Harvard Medical School have taken a close look at a key host-pathogen interaction occurring during the notorious disease anthrax, caused by the bacterial pathogen Bacillus anthracis. Their research, published recently in Current Biology [1] , focuses on the pivotal interactions between one of the pathogen's central virulence factors, anthrax lethal toxin (LeTx), and one of the host's central defensive cells, the macrophage. They have identified a gene that determines whether mouse macrophages are resistant or sensitive to LeTx, and which turns out to encode a kinesin-like motor protein.
Systemic anthrax is an overwhelming and often fatal bacterial infection that is a frank veterinary disease and quite rare in humans (see [2] [3] [4] [5] for reviews). Systemic anthrax in humans is initiated when dormant B. anthracis spores enter the body via inhalation, ingestion of meat from animals that have died of the disease, or spread from a localized lesion associated with the milder cutaneous form of the disease [2] . During inhalation anthrax, endospores are taken up by phagocyte cells in the lungs and are carried to the draining mediastinal and peribronchial lymph nodes. Inhalation anthrax is not a true pneumonia: the lungs act as the portals to the body. Spores break dormancy, escape into the blood and multiply there to high numbers, sometimes exceeding 10 8 vegetative Gram-positive bacilli per millilitre of blood. Initial symptoms are vague, 'flu like' and usually occur 5-10 days after exposure, but they can sometimes occur either earlier or up to six weeks after exposure, probably reflecting differences in absolute numbers of endopsores inhaled or the time it takes spores to be scavenged by alveolar macrophages. A few days after onset of initial symptoms, the disease takes its fulminant course, usually resulting in death if treatment was not begun before the symptoms appear. Extrapolated from studies with non-human primates, it is estimated that an ID 50 for humans is in the range of 8,000-50,000 spores.
At the center of lethal anthrax pathologies lies the toxin LeTx, made up of two proteins, encoded on virulence plasmid pXO1, which act in concert. The protective antigen (PA) binds to host cells and 'injects' the catalytic protein, lethal factor (LF), into the cytoplasm [2, 5] . In the cytoplasm, LF acts as a zinc-metalloprotease that has been shown to cleave MAP kinase kinase [6] . LeTx is intimately involved with the course of infection [5] : PA-or LF-minus anthrax strains are attenuated; animals challenged with purified LeTx present symptoms closely mimicking those of an anthrax infection (including death); and passive or active immunity to PA protect against spore challenge (hence the name 'protective antigen'). The macrophage itself appears to be the central arena of LeTx activities. Although LeTx can enter most cells types, macrophages are uniquely susceptible, lysing in about 2 hours in culture [7] . They may also play a larger role in LeTx toxicity, as mice without a full complement of macrophages are resistant to lethal doses of the toxin [8] . These professional phagocytes, prevalent throughout the body, are a key component in innate immunity. They also are capable of initiating hyperinflammatory cascades involved with many forms of septic and toxic shock [2, 8] .
In a series of elegant experiments, Dietrich's group [1] has exploited the innate differences in sensitivities to LeTx between inbred strains of mice to discover a single gene that determines macrophage sensitivity to the cytotoxic action of LeTx. In earlier work [9, 10] , the group found that macrophages from various inbred mouse strains fall into two groups: those readily killed by LeTx, and those that are toxin-resistant. This paralleled the patterns reported in the toxin-sensitivities of the animals themselves. By cross-breeding and genetic analyses, the group determined that the sensitive versus resistant phenotype is controlled by a region on chromosome 11, which they named the ltxs1 (lethal toxin sensitivity) locus.
In their new work [1] , the Dietrich group used positional cloning to show that polymorphisms in a single gene in the ltxs1 region, kif1C, is responsible for the sensitivity groupings. The product of this gene, Kif1C, turns out to be a kinesin-like motor protein of the UNC104 subgroup, involved in cellular transport systems. The results show that the two susceptibility groups appear identical in the early steps of intoxication, which include binding to membrane surface receptors, toxin processing and activation, and uptake into endosomes and delivery of the LF moiety into the cytoplasm. From the data, the authors conclude that, despite the likely role of Kif1C in intracellular transport, the kif1C polymorphisms do not appear to affect early LeTx events but rather those occurring after entry, though Kif1C's exact role remains to be determined.
There are also two interesting surprises arising from this study. The first is that it is macrophages carrying the wildtype kif1C gene that are resistant to LeTx killing, and it is the mutated versions of this gene that give rise to the sensitive phenotype. This is surprising as most species and their macrophages are not considered resistant to the effects of LeTx, though mice may be a bit more so than other species. One might have predicted, beforehand, that wildtype Kif1C might correlate with the prominent sensitive phenotype observed. The second surprise is that MAP kinase kinase, a cytoplasmic substrate of LF enzymatic activity, is equivalently cleaved in both sensitivity groups. This finding now places the effects of the kif1C polymorphism downstream of the toxin's catalytic activities, and perhaps questions whether MAP kinase kinase inactivation by LF is involved directly in the toxic cascade.
Although we are far from having a complete understanding of all the steps in anthrax LeTx actions, these new studies enhance our understanding of anthrax and identify a single host gene that predicates mouse sensitivity or resistance to this important virulence factor. Any role that Kif1C might play in human anthrax needs to investigated further, and the role of LeTx in anthrax remains an important area of future research. It has been suggested that therapies that neutralize the LeTx might be useful in supplementing conventional antibiotics in the instance of human anthrax. Two approaches now being considered in this area are passive administration of neutralizing antibodies and use of a dominant-negative form of the PA protein that blocks the entry of LF into cells [11, 12] . With the atomic structure of PA solved [13] and the structure of LF expected to be available soon, it also may be possible to design small molecules that interfere with LeTx action. Whether any toxin-centered therapeutic might be useful within the tight timetable presented in cases of systemic anthrax will depend upon both pharmacological effectiveness and whether the drug can be administered before the toxin can perform its deadly functions. The window of opportunity might turn out to be before, or immediately after, onset of symptoms. This is much the same scenario as we encounter currently with the microbe and conventional antibiotics such as penicillin and Ciprofloxacin.
